NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (https://www.inflam.com), is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ...
An expert discusses how rilzabrutinib, a recently FDA-approved Bruton tyrosine kinase (BTK) inhibitor, targets the autoimmune ...
News-Medical.Net on MSN
Decoding the signaling networks and metabolic dysregulation underlying sepsis
Background： Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback